A Second View: Discussing 89bio’s pegozafermin in severe hypertriglyceridemia, following Phase 2 Data ResultsTicker(s): ETNB
Institution: Renown Medical Center Institute for Heart and Vascular Health (Nevada)
- Medical Director of Vascular Medicine and Anticoagulation Services at the Renown Medical Center Institute for Heart and Vascular Health; served as Vice President of the Board of the American Society of Hypertension (ASH).
- Manages hundreds of patients with hypertension, about ~40 patients with lp(a) >150 mg/dl, and <150 patients with SHTG
- Clinical Interests include management of hypertension, dyslipidemia, anticoagulation, vascular disease, and heart disease and stroke prevention.
- Principal investigator on numerous clinical trials, most recently focused in the field of device therapy for hypertension. Research focused on diagnosis and management of renovascular disease and exploring novel means of overcoming barriers to hypertension and dyslipidemia control.
Please describe your clinical practice. How many patients with SHTG do you see on a yearly basis? Could you talk to us about the standard of care?
How well do patients respond to treatment with fenofibrate and omega-3 fatty acid therapy or Epanova, and how does it stand up to new and emerging treatment options? How critical is the need for new drugs?
Can you talk to us about the mechanism of action of glycoPEGylated analogs of fibroblast growth factor 21 (FGF21) ? What are the benefits specific to pegozafermin, how important is the extended half-life ?
How often do patients develop pancreatitis? What approach works best to prevent that from happening?Added By: dami_admin
Could you please share your thoughts on the Phase 2 results, where 88% of treated patients vs. 0% of placebo patients achieved a ≥30% reduction in liver fat from baseline and 24% of treated patients vs. 0% of placebo patients achieved normalized levels of liver fat at week.https://ir.89bio.com/news-releases/news-release-details/89bio-presents-positive-results-entrigue-pha...Added By: dami_admin
Please discuss the findings showing non-HDL-C reductions in both apo-B subtypes, apoB48 and apoB100; can you comment on pegozafermin reducing atherogenic lipoproteins and chylomicrons?
How likely would you be to switch patients to pegozafermin?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.